Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1163-1165

  Jaruratanasirikul, Sutep ^a   Raungsri, Nuntida ^a   Punyo, Jarurat ^a   Sriwiriyajan, Somchai ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

lactams; Carbapenems; Pharmacodynamics

Indexed keywords

IMIPENEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; STATISTICAL ANALYSIS; VOLUNTEER;

ADULT; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 29444440413     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki375     Document Type: Article

References (10)

1. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
2. Vogelman B, Gudmundsson S, Leggett J et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-47.
3. Norrby SR, Faulkner KL, Newell PA. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract 1997; 6: 291-303.
4. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
5. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003; 17: 479-501.
6. Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactam for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002; 46: 2327-32.
7. Garcia-Capdevila L, Lopez-Calull C, Arroyo C et al. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B 1997; 692: 127-32.
8. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl 1: S42-S50.
9. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003; 52: 518-21.
10. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-h infusion or bolus injection. Antimicrob Agents Chemother 2005; 49: 1337-9.